Inhalational Anthrax
📧 Sign up to get email alerts when something new happens for Inhalational Anthrax.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario [Phase 4]
Phase 4 trial update assessing the clinical benefit and safety of raxibacumab in patients with symptomatic inhalational anthrax in a mass ex…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
A clinical trial evaluating the clinical benefit and safety of Anthrax Immune Globulin Intravenous (ANTHRASIL/AIGIV) in patients with inhala…
-
FDA approval · 2021-06-02FDA Approved: RAXIBACUMAB — Supplemental Application (Emergent Manufacturing Operations Baltimore LLC)
FDA approved a supplemental application for manufacturing operations of RAXIBACUMAB (raxibacumab) by Emergent Manufacturing Operations Balti…
-
FDA approval · 2019-11-29FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)
FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.
-
CLINICAL_TRIALS trial_result · 2019-05-01Clinical Trial Update: Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers [Phase 1]
Phase 1 intramuscular dose-escalation study of ETI-204 in adult volunteers has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-04-22Clinical Trial Update: Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers [Phase 1]
Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of repeat IV administration of ETI-204 in healthy adult volunteers.
-
CLINICAL_TRIALS trial_result · 2019-04-08Clinical Trial Update: Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers [Phase 1]
Phase 1 study evaluating safety, tolerability, and pharmacokinetics of IV ETI-204 alone and with ciprofloxacin in healthy adult volunteers (…
-
CLINICAL_TRIALS trial_result · 2019-04-08Clinical Trial Update: Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers [Phase 1]
Phase 1 trial updates safety, tolerability, and pharmacokinetics of a single IV dose of ETI-204 in adults.
-
FDA approval · 2018-01-11FDA Approved: RAXIBACUMAB — Supplemental Application (Emergent Manufacturing Operations Baltimore LLC)
The FDA approved a supplemental application to support manufacturing operations for the biologic Raxibacumab, submitted by Emergent Manufact…
-
FDA approval · 2016-10-20FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)
FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.
-
FDA approval · 2016-03-18FDA Approved: ANTHIM — Original Application (Elusys Therapeutics, Inc.)
FDA approved ANTHIM (obiltoxaximab) from Elusys Therapeutics as an original application for the treatment of inhalational anthrax in combina…
-
FDA approval · 2012-12-14FDA Approved: RAXIBACUMAB — Original Application (Emergent Manufacturing Operations Baltimore LLC)
FDA approved raxibacumab under an original biologics license application for treatment of inhalational anthrax when used with antibiotics. T…